Friday 23rd April - Professor Andrew Porter “Commercialising Biotechnology”
Andrew Porter is Professor of Biotechnology and Deputy Director of the Institute of Medical Sciences at the University of Aberdeen. He was founder and CSO of University spin-out Haptogen Ltd. which was acquired by Wyeth in October 2007.
Haptogen developed a proprietary human therapeutic antibody platform designed for discovery and optimization of protein therapeutics with improved profiles. The benefits include the potential for more convenient routes of administration as well as cell and organ penetration, addressing diseases that are not treatable with first generation protein therapeutics.
Prior to Haptogen, Prof. Porter was one of the founding academics and Research Director of Remedios Ltd, Aberdeen. Remedios, a biosensor company, was Scottish biotech of the year in 2000.
In 2005 Prof. Porter was Ernst and Young Plc, Scottish & UK Science and Technology Entrepreneur of the Year and in 2006 be became a Fellow of the Royal Society of Edinburgh.
Since the sale of Haptogen, Prof. Porter has remained active within the biotechnology sector and together with his Haptogen co-founders he has established a venture fund, Grampian Bio-partners, that recently made its first investment in an anti-infectives company based in Scotland.
Prof. Porter was recently appointed to the BioIndustries Association (BIA) Scotland Committee
This event forms part of the TCD/UCD Innovation Alliance Programme of Events.
| Professor Andrew Porter “Commercialising Biotechnology” | |
| Date: | Friday 23rd April |
|---|---|
| Time: | 4PM |
| Venue: | Joly Lecture Theatre, Hamilton Building, TCD |
| Speaker: | Professor Andrew Porter |
| Organiser: | The TCD Technology Transfer Office and School of Biochemistry and Immunology TCD |
| Contact: | gordon.elliott@tcd.ie |
| Audience: | All welcome |
